ATE Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 7.94%

Insider Buying (Last 12 Months): C$19,600.00

Insider Selling (Last 12 Months): C$0.00

Antibe Therapeutics Insider Trading History Chart

Antibe Therapeutics Share Price & Price History

C^$0.00

+0.30 (1.20%)

As of 04/8/2024 10:01 PM ET

Days: 30 | 90 | 365

The next companies to potentially benefit thanks to Nvidia are …

From Weiss Ratings | Ad

Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.

Click here to learn more.

Antibe Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/7/2024	Daniel Marcel Legault	Director	Buy	20,000	C$0.50	C$10,000.00
3/6/2024	Joseph Stauffer	Senior Officer	Buy	24,000	C$0.40	C$9,600.00
11/15/2022	Daniel Marcel Legault	Director	Buy	40,000	C$0.49	C$19,400.00	983,296
11/15/2022	Scott Wilson Curtis	Senior Officer	Buy	20,000	C$0.50	C$10,000.00	100,000
7/15/2022	John Lawrence Wallace	Director	Sell	5,000	C$0.62	C$3,100.00	1,772,976
7/11/2022	Daniel Marcel Legault	Director	Buy	7,500	C$0.60	C$4,500.00	888,796
7/8/2022	Scott Wilson Curtis	Senior Officer	Buy	20,000	C$0.62	C$12,400.00	80,000
7/7/2022	John Lawrence Wallace	Director	Sell	21,500	C$0.62	C$13,330.00	1,899,576
11/10/2021	Walter Minnes Macnee	Director	Buy	50,000	C$0.90	C$45,000.00	497,027
11/3/2021	Walter Minnes Macnee	Director	Buy	25,000	C$0.98	C$24,385.00	447,027
11/1/2021	Daniel Marcel Legault	Director	Buy	2,500	C$0.92	C$2,300.00	778,796
11/1/2021	Scott Wilson Curtis	Senior Officer	Buy	13,000	C$0.88	C$11,440.00	60,000
8/4/2021	Daniel Marcel Legault	Director	Buy	12,500	C$1.02	C$12,750.00	776,296

Obama wins Presidential debate

From Porter & Company | Ad

When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.”

Please, watch this now before it’s too late.

SEC Filings (Institutional Ownership Changes) for Antibe Therapeutics (TSE:ATE)

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Today's Range

Now: N/A

50 Day Range

MA: C$0.30

C$0.30

52 Week Range

Now: N/A

Volume

167,042 shs

Average Volume

135,475 shs

Market Capitalization

C$15.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.19

Who are the company insiders with the largest holdings of Antibe Therapeutics?: Antibe Therapeutics' top insider investors include:
Daniel Marcel Legault (Director)
Scott Wilson Curtis (Senior Officer)
Joseph Stauffer (Senior Officer)
Learn More about top insider investors at Antibe Therapeutics.